Irini Chatziralli1,2, George Theodossiadis3, Stamatina A Kabanarou4, Efstratios Parikakis5, Tina Xirou4, Panagiotis Mitropoulos5, Panagiotis Theodossiadis6. 1. 2nd Department of Ophthalmology, "Attikon" Hospital, National and Kapodistrian University of Athens, Athens, Greece. eirchat@yahoo.gr. 2. , 1 Rimini Street, Haidari, 12462, Athens, Greece. eirchat@yahoo.gr. 3. 2nd Department of Ophthalmology, Henry Dunant Hospital, Athens, Greece. 4. Medical Retina Department, Korgialeneio Benakeio, Red Cross Hospital, Athens, Greece. 5. 2nd Department of Ophthalmology, Ophthalmiatrion Athinon, Athens, Greece. 6. 2nd Department of Ophthalmology, "Attikon" Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Abstract
PURPOSE: To compare intravitreal ranibizumab and dexamethasone implant in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO). METHODS:Participants were 42 treatment naive patients with ME due to CRVO, who received either intravitreal 0.5 mg ranibizumab (n = 25) or intravitreal 0.7 mg dexamethasone implant (n = 17). The main outcomes included the mean change in best corrected visual acuity (BCVA) and central subfield thickness (CST) at month 12 compared to baseline in the two groups. RESULTS: At month 12, there was no statistically significant difference in BCVA andCST change between the two groups. However, there was recurrence in ME at month 5 in the dexamethasone group. CONCLUSIONS: Both ranibizumab and dexamethasone implant were found to be safe and effective at the 12-month follow-up in patients with ME secondary to CRVO. Since there was a recurrence in ME at month 5 in the dexamethasone group, we suggested that intravitreal injection of dexamethasone implant should be potentially administered sooner than 6 months.
RCT Entities:
PURPOSE: To compare intravitreal ranibizumab and dexamethasone implant in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO). METHODS:Participants were 42 treatment naive patients with ME due to CRVO, who received either intravitreal 0.5 mg ranibizumab (n = 25) or intravitreal 0.7 mg dexamethasone implant (n = 17). The main outcomes included the mean change in best corrected visual acuity (BCVA) and central subfield thickness (CST) at month 12 compared to baseline in the two groups. RESULTS: At month 12, there was no statistically significant difference in BCVA and CST change between the two groups. However, there was recurrence in ME at month 5 in the dexamethasone group. CONCLUSIONS: Both ranibizumab and dexamethasone implant were found to be safe and effective at the 12-month follow-up in patients with ME secondary to CRVO. Since there was a recurrence in ME at month 5 in the dexamethasone group, we suggested that intravitreal injection of dexamethasone implant should be potentially administered sooner than 6 months.
Entities:
Keywords:
Central retinal vein occlusion; Dexamethasone; Inflammation; Ranibizumab; Treatment
Authors: Rachel L McIntosh; Sophie L Rogers; Lyndell Lim; Ning Cheung; Jie Jin Wang; Paul Mitchell; Jonathan W Kowalski; Hiep P Nguyen; Tien Yin Wong Journal: Ophthalmology Date: 2010-06 Impact factor: 12.079
Authors: Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young Hee Yoon; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup; Joanne Li Journal: Ophthalmology Date: 2011-07-20 Impact factor: 12.079
Authors: Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio Journal: Ophthalmology Date: 2011-06-29 Impact factor: 12.079
Authors: C Chiquet; C Dupuy; A M Bron; F Aptel; M Straub; R Isaico; J P Romanet; C Creuzot-Garcher Journal: Graefes Arch Clin Exp Ophthalmol Date: 2015-02-12 Impact factor: 3.117
Authors: Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young-Hee Yoon; Marie-Louise Jacques; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup Journal: Ophthalmology Date: 2010-04-24 Impact factor: 12.079
Authors: Cláudia Farinha; João Pedro Marques; Elisabete Almeida; Alda Baltar; Ana Rita Santos; Pedro Melo; Miguel Costa; João Figueira; Maria Luz Cachulo; Isabel Pires; Rufino Silva Journal: Ophthalmic Res Date: 2015-11-06 Impact factor: 2.892
Authors: I Chatziralli; G Theodossiadis; S A Kabanarou; P Theodossiadis Journal: Graefes Arch Clin Exp Ophthalmol Date: 2017-07-27 Impact factor: 3.117